Susquehanna International Group, LLP Fibrogen Inc Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

28 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$0.33 - $1.26 $42,537 - $162,414	-128,900 Reduced 35.92%	230,000 $92,000
Q2 2024 Aug 15, 2024	BUY	$0.89 - $2.36 $99,947 - $265,028	112,300 Added 45.54%	358,900 $319,000
Q1 2024 May 07, 2024	BUY	$0.73 - $2.73 $180,018 - $673,218	246,600 New	246,600 $579,000
Q3 2023 Nov 14, 2023	SELL	$0.79 - $2.83 $669,604 - $2.4 Million	-847,600 Reduced 95.89%	36,300 $31,000
Q2 2023 Aug 11, 2023	BUY	$2.49 - $20.59 $1.75 Million - $14.5 Million	703,500 Added 389.97%	883,900 $2.39 Million
Q1 2023 May 16, 2023	SELL	$15.95 - $25.18 $381,205 - $601,802	-23,900 Reduced 11.7%	180,400 $3.37 Million
Q4 2022 Feb 14, 2023	SELL	$13.27 - $17.73 $349,001 - $466,299	-26,300 Reduced 11.41%	204,300 $3.27 Million
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $127,680 - $163,520	-11,200 Reduced 4.63%	230,600 $3 Million
Q2 2022 Aug 15, 2022	BUY	$7.94 - $12.96 $1.1 Million - $1.8 Million	138,600 Added 134.3%	241,800 $2.55 Million
Q1 2022 May 16, 2022	SELL	$12.02 - $16.79 $186,310 - $260,245	-15,500 Reduced 13.06%	103,200 $1.24 Million
Q4 2021 Feb 14, 2022	SELL	$9.93 - $15.39 $32,769 - $50,787	-3,300 Reduced 2.7%	118,700 $1.67 Million
Q3 2021 Nov 15, 2021	SELL	$10.18 - $26.64 $50,900 - $133,200	-5,000 Reduced 3.94%	122,000 $1.25 Million
Q2 2021 Aug 11, 2021	BUY	$18.57 - $35.68 $596,097 - $1.15 Million	32,100 Added 33.83%	127,000 $3.38 Million
Q1 2021 May 17, 2021	SELL	$31.0 - $55.72 $713,000 - $1.28 Million	-23,000 Reduced 19.51%	94,900 $3.29 Million
Q4 2020 Feb 16, 2021	BUY	$37.09 - $48.97 $882,742 - $1.17 Million	23,800 Added 25.29%	117,900 $4.37 Million
Q3 2020 Nov 16, 2020	BUY	$40.47 - $45.5 $1.2 Million - $1.35 Million	29,700 Added 46.12%	94,100 $3.87 Million
Q2 2020 Aug 14, 2020	BUY	$32.57 - $42.83 $485,293 - $638,167	14,900 Added 30.1%	64,400 $2.61 Million
Q1 2020 May 15, 2020	BUY	$23.3 - $45.96 $619,780 - $1.22 Million	26,600 Added 116.16%	49,500 $1.72 Million
Q4 2019 Feb 14, 2020	SELL	$34.58 - $48.06 $556,738 - $773,766	-16,100 Reduced 41.28%	22,900 $982,000
Q3 2019 Nov 14, 2019	SELL	$36.98 - $48.45 $558,398 - $731,595	-15,100 Reduced 27.91%	39,000 $1.44 Million
Q2 2019 Aug 14, 2019	SELL	$35.13 - $55.53 $4.28 Million - $6.76 Million	-121,700 Reduced 69.23%	54,100 $2.44 Million
Q1 2019 May 15, 2019	BUY	$42.83 - $59.91 $3.65 Million - $5.11 Million	85,300 Added 94.25%	175,800 $9.56 Million
Q4 2018 Feb 14, 2019	BUY	$37.97 - $60.16 $1.82 Million - $2.88 Million	47,900 Added 112.44%	90,500 $4.19 Million
Q3 2018 Nov 14, 2018	SELL	$56.3 - $67.25 $3.45 Million - $4.12 Million	-61,200 Reduced 58.96%	42,600 $2.59 Million
Q2 2018 Aug 14, 2018	BUY	$44.9 - $64.95 $1.31 Million - $1.89 Million	29,100 Added 38.96%	103,800 $6.5 Million
Q1 2018 May 15, 2018	SELL	$45.35 - $61.65 $18,140 - $24,660	-400 Reduced 0.53%	74,700 $3.45 Million
Q4 2017 Feb 14, 2018	BUY	$41.95 - $60.1 $943,875 - $1.35 Million	22,500 Added 42.78%	75,100 $3.56 Million
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $1.76 Million - $2.84 Million	52,600	52,600 $2.83 Million

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

Primecap Management CO Pasadena, CA

9.91M
Shares

$3.47 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

6.8M
Shares

$2.38 Million
0.05% of portfolio
Vanguard Group Inc Valley Forge, PA

5.88M
Shares

$2.06 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

3.91M
Shares

$1.37 Million
0.0% of portfolio
Black Rock Inc. New York, NY

2.41M
Shares

$843,377
0.0% of portfolio

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account